A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

NCT02954094 · tracked via the Priya Life Science USA tracker

Sponsor

Target PharmaSolutions, Inc.

Phase

Observational

Started

2016-12

Last updated

2026-04-17

Condition(s) studied

Hepatocellular Cancer

Study summary

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Male or female patients, age ≥18 years 2. Patients with a histological/cytological or radiological diagnosis of HCC (mixed HCC cholangiocarcinoma may be included; patients who are candidates for surgical and non-surgical treatment, as well as those being followed without specific HCC therapy may be included) Exclusion Criteria: 1\. Inability to provide written informed consent

Primary outcome measure(s)

Establish a longitudinal observational cohort to understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice — Up to 15 years

Trial sites (71)

Facility	City	Region
Banner University Medical Center	Phoenix	Arizona
University of Arkansas	Little Rock	Arkansas
University of Southern California/Norris Comprehensive Cancer Center	Los Angeles	California
Stanford University	Palo Alto	California
California Liver Research Institute	Pasadena	California
University of California-Davis	Sacramento	California
University of California	San Francisco	California
Georgetown University	Washington D.C.	District of Columbia
Gastro Florida	Clearwater	Florida
University of Florida Hepatology Research at CTRB	Gainesville	Florida
University of Florida Health Gastroenterology	Jacksonville	Florida
Schiff Center for Liver Diseases/University of Miami	Miami	Florida
Tampa General Medical Group	Tampa	Florida
Piedmont Atlanta Hospital	Atlanta	Georgia
Piedmont Cancer Institute	Atlanta	Georgia
Emory University Hospital	Atlanta	Georgia
Northwestern University Division of Gastroenterology and Hepatology	Chicago	Illinois
Rush University Medical Center	Chicago	Illinois
University of Chicago	Chicago	Illinois
University of Iowa Hospitals and Clinics	Iowa City	Iowa
Tulane University	New Orleans	Louisiana
Mercy Medical Center, GI Research	Baltimore	Maryland
Johns Hopkins University	Baltimore	Maryland
Beth Israel Deaconess Medical Center	Boston	Massachusetts
University of Michigan	Ann Arbor	Michigan
Henry Ford Health System	Detroit	Michigan
Mayo Clinic	Rochester	Minnesota
Southern Therapy and Advanced Research (STAR) LLC	Jackson	Mississippi
Saint Louis University	St Louis	Missouri
University of Nebraska Medical Center	Omaha	Nebraska
Rutgers-Robert Wood Johnson Medical School	New Brunswick	New Jersey
Northwell Health - Center for Liver Diseases	Manhasset	New York
NYU Langone Health	New York	New York
Weill Cornell Medical College	New York	New York
Columbia University	New York	New York
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina
Center for Liver Disease and Transplant at CMC	Charlotte	North Carolina
Providence Health & Services Cancer Clinical Trials	Portland	Oregon
Penn State Hershey Medical Center	Hershey	Pennsylvania
University of Pennsylvania	Philadelphia	Pennsylvania

+ 31 more sites — see the full list on the official registry below.

More Target PharmaSolutions, Inc. trials in the USA

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC Active, not recruiting

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease Active, not recruiting

An Observational Study of Patients With Chronic Gastrointestinal Disease Active, not recruiting

An Observational Study of Patients With Dermatologic Disease Starting soon

An Observational Study of Patients With Chronic Liver Disease Enrolling by invitation

Other trials for the same condition

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk Active, not recruiting

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors Active, not recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) Recruiting

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02954094 on ClinicalTrials.gov ↗ ← All trials in the USA